{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:13:16Z","timestamp":1790903596111,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.rmed.2026.108708","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:34:18Z","timestamp":1770424458000},"page":"108708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Amikacin exposure and its association with ototoxicity and efficacy in nontuberculous mycobacterial pulmonary disease treatment"],"prefix":"10.1016","volume":"253","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5272-2249","authenticated-orcid":false,"given":"Fumiya","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9498-6995","authenticated-orcid":false,"given":"Masashi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1208-7698","authenticated-orcid":false,"given":"Koji","family":"Furuuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1139-1604","authenticated-orcid":false,"given":"Keiji","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0722-5861","authenticated-orcid":false,"given":"Takashi","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6908-0921","authenticated-orcid":false,"given":"Eriko","family":"Hachikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9041-5589","authenticated-orcid":false,"given":"Kazuhiko","family":"Hanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2026.108708_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2026.108708_bib2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.rmed.2006.04.002","article-title":"A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease","volume":"101","author":"Kobashi","year":"2007","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2026.108708_bib3","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","article-title":"Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease","volume":"174","author":"Griffith","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2026.108708_bib4","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1128\/AAC.00961-16","article-title":"Amikacin optimal exposure targets in the hollow-fiber system model of tuberculosis","volume":"60","author":"Srivastava","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.rmed.2026.108708_bib5","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1128\/AAC.02282-15","article-title":"Amikacin pharmacokinetics\/pharmacodynamics in a novel hollow-fiber Mycobacterium abscessus disease model","volume":"60","author":"Ferro","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.rmed.2026.108708_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03222-23","article-title":"Time-dependent pharmacodynamics of amikacin on Mycobacterium abscessus growth and resistance emergence","volume":"12","author":"Gibson","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.rmed.2026.108708_bib7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jiac.2020.09.033","article-title":"A meta-analysis of the target trough concentration of gentamicin and amikacin for reducing the risk of nephrotoxicity","volume":"27","author":"Yamada","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.rmed.2026.108708_bib8","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1592\/phco.19.16.1252.30876","article-title":"Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside","volume":"19","author":"Murry","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.rmed.2026.108708_bib9","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.1128\/AAC.01050-15","article-title":"Amikacin concentrations predictive of ototoxicity in multidrug-resistant tuberculosis patients","volume":"59","author":"Modongo","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.rmed.2026.108708_bib10","first-page":"818","article-title":"Once-daily dosing of amikacin for treatment of Mycobacterium abscessus lung disease, Int. J. Tuberc","volume":"21","author":"Lee","year":"2017","journal-title":"Lung Dis."},{"key":"10.1016\/j.rmed.2026.108708_bib11","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3389\/fncel.2017.00308","article-title":"Aminoglycoside-induced cochleotoxicity: a review","volume":"11","author":"Jiang","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.rmed.2026.108708_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijporl.2019.02.002","article-title":"Genetic susceptibility to aminoglycoside ototoxicity","volume":"120","author":"Nguyen","year":"2019","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"10.1016\/j.rmed.2026.108708_bib13","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1086\/420742","article-title":"Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases","volume":"38","author":"Peloquin","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.rmed.2026.108708_bib14","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/jac\/dkr221","article-title":"Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice","volume":"66","author":"Sturdy","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.rmed.2026.108708_bib15","first-page":"905","article-title":"The incidence of amikacin ototoxicity in multidrug-ResistantTuberculosis patients","volume":"10","author":"Javadi","year":"2011","journal-title":"Iran. J. Pharm. Res. (IJPR)"},{"key":"10.1016\/j.rmed.2026.108708_bib16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/resp.12676","article-title":"Safety of IV amikacin in the treatment of pulmonary non-tuberculous mycobacterial disease","volume":"21","author":"Ellender","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.rmed.2026.108708_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01400-16","article-title":"Reduced chance of hearing loss associated with therapeutic drug monitoring of aminoglycosides in the treatment of multidrug-resistant tuberculosis","volume":"61","author":"van Altena","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.rmed.2026.108708_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40360-019-0302-1","article-title":"Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada","volume":"20","author":"Aznar","year":"2019","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"Suppl 2","key":"10.1016\/j.rmed.2026.108708_bib19","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1007\/s12070-018-1266-y","article-title":"Evaluating hearing loss in patients undergoing second line anti tubercular treatment","volume":"71","author":"Verma","year":"2019","journal-title":"Indian J. Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.rmed.2026.108708_bib20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s12879-016-1689-6","article-title":"Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: a case series","volume":"16","author":"Namkoong","year":"2016","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.rmed.2026.108708_bib21","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1038\/psp.2013.26","article-title":"Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance","volume":"2","author":"Byon","year":"2013","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.rmed.2026.108708_bib22","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.rmed.2026.108708_bib23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1023\/A:1022972420004","article-title":"Use of prior information to stabilize a population data analysis","volume":"29","author":"Gisleskog","year":"2002","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.rmed.2026.108708_bib24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/antibiotics10020100","article-title":"Population pharmacokinetics analysis of amikacin initial dosing regimen in elderly patients","volume":"10","author":"Kato","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.rmed.2026.108708_bib25","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00170-2018","article-title":"Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement","volume":"51","author":"van Ingen","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2026.108708_bib26","series-title":"Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic. Actinomycetes","year":"2023"},{"key":"10.1016\/j.rmed.2026.108708_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.652674","article-title":"Ototoxicity of non-aminoglycoside antibiotics","volume":"12","author":"Rybak","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.rmed.2026.108708_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106219","article-title":"Amikacin pharmacokinetics in elderly patients with severe infections","volume":"175","author":"Medell\u00edn-Garibay","year":"2022","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.rmed.2026.108708_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00993-19","article-title":"Amikacin initial dose in critically ill patients: a nonparametric approach to optimize a priori pharmacokinetic\/pharmacodynamic target attainments in individual patients","volume":"63","author":"Boidin","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.rmed.2026.108708_bib30","first-page":"222","article-title":"Study of mitochondrial DNA A1555G and C1494T mutations in a large cohort of women individuals, mitochondrial DNA A DNA mapp","volume":"30","author":"Wang","year":"2019","journal-title":"Seq. Anal."},{"key":"10.1016\/j.rmed.2026.108708_bib31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4103\/0971-6866.112888","article-title":"Investigation of the A1555G mutation in mitochondrial DNA (MT-RNR1) in groups of Brazilian individuals with nonsyndromic deafness and normal-hearing","volume":"19","author":"Salom\u00e3o","year":"2013","journal-title":"Indian J. Hum. Genet."},{"key":"10.1016\/j.rmed.2026.108708_bib32","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1164\/rccm.201206-1088OC","article-title":"Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease","volume":"186","author":"Koh","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2026.108708_bib33","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.chest.2023.11.038","article-title":"Safety and efficacy of clofazimine as an alternative for rifampicin in Mycobacterium avium complex pulmonary disease treatment: outcomes of a randomized trial","volume":"165","author":"Zweijpfenning","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2026.108708_bib34","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cmi.2023.02.007","article-title":"Towards clinical breakpoints for non-tuberculous mycobacteria\u2013determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution","volume":"29","author":"Fr\u00f6berg","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.rmed.2026.108708_bib35","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1183\/23120541.01084-2024","article-title":"Risk factors, molecular analysis and treatment outcomes of amikacin-resistant Mycobacterium avium complex pulmonary disease","volume":"11","author":"Kodama","year":"2025","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.rmed.2026.108708_bib36","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s12325-023-02436-x","article-title":"Aminoglycoside-related nephrotoxicity and ototoxicity in clinical practice: a review of pathophysiological mechanism and treatment options","volume":"40","author":"Le","year":"2023","journal-title":"Adv. Ther."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126000764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126000764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T07:50:03Z","timestamp":1771833003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126000764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":36,"alternative-id":["S0954611126000764"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108708","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amikacin exposure and its association with ototoxicity and efficacy in nontuberculous mycobacterial pulmonary disease treatment","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108708","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108708"}}